Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
- MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update
June 15, 2022
- MHLW Publishes Guidelines for Evaluating SaMDs Used for Behavioral Modification
June 15, 2022
- Lawmakers’ Group Pushes for Legal Steps to Eliminate Drug Lag for Children
June 14, 2022
- LDP’s COVID HQ Compiles Mid-to-Long Term Proposal for Future Pandemics
June 14, 2022
- MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
- Updated Labels for mRNA Vaccines Flag Risk of Guillain-Barre Syndrome
June 13, 2022
- Japan Mulls Securing AstraZeneca COVID Cocktail If Approved: Minister
June 13, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Pharma Wants Govt Purchase for Novel Antimicrobial, Instead of Favorable Pricing
June 10, 2022
- “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
- MHLW Council OKs Public Knowledge-Based Applications for 3 Drugs Including Acetaminophen
June 9, 2022
- Edurant Label Revised for Combined Use with Vocabria
June 8, 2022
- Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
- AMED Sets to Lay R&D Data Utilization Infrastructure from Current Fiscal Year
June 8, 2022
- Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
- Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
- Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
- Japan Govt to Set Biosimilar Target by March 2023: Honebuto Draft
June 6, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…